Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 11Burkitt Lymphoma 6Myeloproliferative Disorders 2Sarcoma, Myeloid 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Leukemia, Biphenotypic, Acute 1Leukemia 1Hematologic Neoplasms 1Acute Myeloid Leukemia With KMT2A Rearrangement 1

Interventions

Cyclophosphamide 5fludarabine phosphate 3Vincristine 3Methotrexate 3Etoposide 3pegaspargase 2merphos 2dexamethasone acetate 2dexamethasone 21-phosphate 2auricularum 2Whole-Body Irradiation 2Tacrolimus 2Specimen Handling 2Sirolimus 2Peripheral Blood Stem Cell Transplantation 2Leucovorin 2Doxorubicin 2Dexamethasone 2Cytarabine 2Calcium Dobesilate 2venetoclax 1prednylidene 1hydrocortisone hemisuccinate 1fludarabine 1exifone 1deltacortene 1calaspargase pegol 1azathiopurine 1aldesleukin 1Thioguanine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × Daunorubicin × 30 days × Clear all
NCT02112916 2026-06-03

Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
847 enrolled 19 charts
LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡